Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Conditions:   Peanut Allergy;   Multi-food Allergy Interventions:   Drug: Omalizumab;   Drug: Placebo for Omalizumab;   Drug: Multi-Allergen Oral Immunotherapy;   Drug: Placebo for Multi-Allergen Oral Immunotherapy;   Other: Double-Blind Placebo-Controlled Food Challenge Based Treatment Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Genentech, Inc.;   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials